MBOT

Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April The Company added new customers in Q3 while expanding into new states and sites of service HINGHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission (SEC). As disclosed in its July 7, 2026 press release, the Company generated greater than 100% revenue and customer growth compared to the first quarter ended March 31, 2026. Second Quarter Highlights Commenced the Full Market Release (FMR) of the LIBERTY System during The Society of Interventional Radiology (SIR) Annual Scientific Meeting in April 2026. New health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania adopted the LIBERTY System, joining Georgia, Florida, and New York, which adopted the LIBERTY System during the Limited Market Release (LMR). Increased the number of hospital sites using the LIBERTY System across existing customer health systems. Procedure volume increased in the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, as customers expanded deployment to additional sites and migrated more users to the LIBERTY System. The LIBERTY System was used across a variety of procedure types, including Prostatic Artery Embolization (PAE), Y-90 Radioembolization, Genicular Artery Embolization (GAE) and Uterine Artery Embolization (UAE), showcasing the versatility of the LIBERTY System. Total revenue was up more than 100% compared to the first quarter of 2026. Having successfully completed the Limited Market Release in April 2026, and with its associated costs partially being accounted for in the second quarter of 2026, coupled with other cost reduction activities which are being implemented, the Company believes it will substantially reduce its cost of revenue which increased in the three-month period ended June 30, 2026 compared to the three-month period ended March 31, 2026. Entered into an agreement with Lovell Government Services Inc. to serve federal healthcare systems, enabling access to more than 2,000 government healthcare facilities. High customer satisfaction is reported and reflected in repeat customer orders for the LIBERTY System as more sites and users are trained on the system. Broadened its sales footprint to eight sales territories compared to four sales territories at the end of March 2026, allowing the Company to be on track to have 12 territories across the U.S. by year-end. Entered into an agreement with Sanmina and is in the process of establishing a second manufacturing site to expand production capacity to support anticipated demand in the U.S. and international markets, as well as future cost reduction initiatives. Achieved a significant regulatory milestone as Israel became the second jurisdiction — and the first outside of the U.S. — to grant marketing clearance for the LIBERTY System. Awarded the 2026 Innovative Start-Up Award from Surgical Robotics Technology (SRT), which recognizes companies with outstanding technological and commercial progress through highly innovative, groundbreaking technologies.1 “We achieved a number of key milestones during the second quarter and first half of 2026, including the successful transition from our Limited Market Release to the Full Market Release earlier in the quarter,” commented Harel Gadot, CEO, President and Chairman. “This resulted in the high growth we saw in both adoption and utilization, leading to a major increase in revenue from the prior period. We are continuing to enhance our commercial team, expand our sales footprint and work closely with existing accounts to expand U.S. sites and increase utilization. At the same time, we continue to implement cost reduction initiatives to lower the cost of revenues. Internationally, we continue to establish a global infrastructure and implement our commercial readiness plans in Europe in anticipation of obtaining a CE Mark.” LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. About Microbot MedicalMicrobot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Learn more at www.microbotmedical.com and connect on LinkedIn and X. Safe Harbor Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Contacts: [email protected]@microbotmedical.com https://www.surgicalroboticstechnology.com/surgical-robotics-industry-awards/categories/

The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026. The performance reflects the successful commencement of the Full Market Release of the LIBERTY System on April 13, 2026, as health systems in several key markets adopted the system during the second quarter, including leading health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania. In addition, the Company entered into an agreement with Lovell Government Services Inc. to serve federal healthcare systems, such as the Veterans Health Administration (VHA), a division of the U.S. Department of Veterans Affairs, the Military Health System (MHS), which is run by the U.S. Department of War, and the Indian Health Service (IHS). Furthermore, health systems that had adopted the LIBERTY System during the Limited Market Release (LMR) have increased their procedure volume in the second quarter ended June 30, 2026, due to site expansion and more users migrating to the system, compared to the first quarter ended March 31, 2026. With the rising interest from leading health systems, the Company broadened its sales footprint from 4 to 8 sales territories during the second quarter of 2026 and is on track to have 12 territories across the U.S. by the end of the year. Moreover, the Company recently received marketing clearance for the LIBERTY System from the Israeli Ministry of Health's AMAR Division, making Israel the first country outside of the U.S. to approve the system. To ensure the Company has the capacity to meet current and future demand, it recently entered into an agreement to establish a second manufacturing site, positioning the Company for potential long-term margin expansion as volumes scale. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Learn more at www.microbotmedical.com and connect on LinkedIn and X. Safe Harbor Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Contacts: [email protected]@microbotmedical.com

Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across multiple sales territories Company experiencing increase in recurring customer orders, new accounts and growing pipeline of potential future accounts HINGHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it recorded revenue during its fiscal quarter ended March 31, 2026, benefiting from the Limited Market Release (LMR) of the LIBERTY System which took place during that period. Earlier this quarter, the Company commenced the Full Market Release (FMR) of the LIBERTY system, and revenue mid-way through the second quarter has already exceeded total first quarter revenue, driven by the number of accounts since the end of the LMR having more than doubled. Currently, hospitals in six states have adopted the LIBERTY system, including Georgia, Florida, New York, Michigan, Massachusetts, and North Carolina. Earlier this month, Boston (MA) became the first city and state in which the Company has multiple accounts using the LIBERTY system, which the Company believes reflects growing commercial momentum. This demonstrates that interest from physicians and hospitals is translating into new accounts across key sales territories, including two of the three sites that participated in the ACCESS-PVI pivotal clinical trial, which serves as a strong validation of the added value that it brings. Moreover, the breadth of the procedures that have been performed using the LIBERTY System includes what the Company believes is the world’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH), robotic Genicular Artery Embolization (GAE), a minimally invasive, non-surgical outpatient procedure designed to treat chronic knee pain, typically caused by osteoarthritis, robotic Y-90 radioembolization mapping and treatment for liver cancer, and others. “Our success during the first quarter was demonstrated across multiple metrics, including the continued progress of the limited market release leading to us commence the Full Market Release, the number of accounts that adopted the LIBERTY system and the users that deployed it for varied procedures,” commented Harel Gadot, Chairman, President and CEO. “Our momentum so far during the second quarter is encouraging and reinforces our confidence as we have more than doubled the number of accounts and expanded our footprint into several new cities and states since the commencement of the Full Market Release. Additionally, we believe that customer enthusiasm and satisfaction remain high, supported by recurring orders to support procedures over the coming weeks and months. Our newest territories in the Midwest and Mid-Atlantic, which were launched in early April, have already secured accounts, further validating our commercial execution strategy, and it emboldens the team as we continue to roll out the commercial strategy to penetrate population-rich regions in the U.S. in the second half of the year along with commercial readiness activities in international markets.” The Company expects commercial adoption to accelerate as recent value-enhancing developments, such as updated guidelines on occupational radiation and musculoskeletal protection adopted by at least nine medical societies and supported by the American Medical Association (AMA), could help drive adoption of the LIBERTY System. These industry tailwinds, along with continued visibility at major conferences such as SIR and the upcoming Annual Global Embolization Symposium & Technologies (GEST) Conference taking place in New York City this week, are expected to support continued U.S. commercial adoption and facilitate the Company’s growth as it builds a global commercial infrastructure. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Learn more at www.microbotmedical.com and connect on LinkedIn and X. Safe Harbor Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Contacts: [email protected] [email protected]

DENTSPLY SIRONA Inc. XRAY is scheduled to release first-quarter 2026 results on May 5, after market close. In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 3.57%. It delivered an average earnings surprise of 7.73% for the trailing four quarters. The Zacks Consensus Estimate for revenues is pegged at $840.1 million. The consensus mark for earnings is pinned at 28 cents per share. Our model estimates for revenues and adjusted earnings per share (EPS) are pinned at $846.2 million and 32 cents, respectively. DENTSPLY SIRONA’s first-quarter 2026 performance is likely have to reflected continued softness in the United States, along with lingering tariff-related pressures. The company remains in the early phase of executing its multi-year “Return-to-Growth” transformation plan, which is expected to weigh on near-term earnings due to elevated investments in innovation, commercial reorganization and clinical education. While these actions are aimed at restoring sustainable growth, they are likely to have kept margins under pressure in the to-be-reported quarter. Tariffs and softer demand trends in key categories like equipment, implants and CAD/CAM solutions are expected to continue in the U.S. market. Management also highlighted a headwind from dealer inventory adjustments, particularly tied to a shift toward a drop-ship model, with roughly $30 million of inventory expected to be worked down in the first half of 2026. These dynamics are likely to have weighed on volumes and revenue visibility in the quarter to be reported. From a segmental standpoint, ongoing weakness in Connected Technology Solutions, implants and orthodontics is likely to have persisted, given competitive pressures and lower procedural volumes. However, relatively stable trends in Essential Dental Solutions, along with continued strength in Wellspect Healthcare, may have provided some support. Distributor inventory levels for equipment and CAD/CAM remained below historical averages exiting 2025, indicating that any recovery is likely to be gradual and dependent on dealer reengagement efforts. On the geographic front, while the U.S. business is expected to have remained under pressure, international markets — particularly Europe — likely continued to demonstrate resilience. Management previously indicated stable end-market conditions outside the United States, which may have helped partially offset domestic weakness in the quarter. Investors are likely to closely monitor signs of stabilization in the U.S. market, progress on dealer partnerships, execution in the implants business and early traction from commercial restructuring initiatives. Although management expects sequential improvement in the second half of 2026, the first quarter is likely to have reflected a transition phase, with benefits from strategic initiatives yet to fully materialize. DENTSPLY SIRONA Inc. price-eps-surprise | DENTSPLY SIRONA Inc. Quote Our proven model does not conclusively predict an earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. XRAY’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +1.98%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. XRAY’s Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #4 (Sell). Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Microbot Medical MBOT has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present. MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure. Henry Schein HSIC has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5. HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure. IDEXX Laboratories IDXX has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Microbot Medical Inc. (MBOT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

InnovAge INNV is scheduled to release third-quarter fiscal 2026 results on May 05, after market close. In the last reported quarter, the company delivered an earnings surprise of 100.00%. The company appears to have entered the second half of fiscal 2026 with strong operational momentum and improving financial visibility. While membership growth is likely to have remained solid, supported by successful Medicaid reinstatements and steady enrollment trends, some normalization is expected as prior tailwinds fade. At the same time, medical cost management and operational efficiencies are likely to have remained favorable, though seasonal pressures such as higher inpatient utilization could weigh modestly on margins. So far this year, INNV’s shares have surged 60.3% against the industry’s fall of 11.6%. The S&P Index has gained 6.5% in the same period. Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings is pegged at 6 cents per share, indicating an increase of 175% year over year. The consensus mark for revenues is pinned at $234.5 million, implying growth of 7.5% from the prior-year reported figure. InnovAge’s upcoming quarterly performance is likely to have reflected continued operational momentum, though some normalization in margins and seasonal pressures could temper near-term upside following a strong first half. The company recently delivered double-digit revenue growth and a sharp improvement in profitability, driven by better execution across its PACE (Program of All-Inclusive Care for the Elderly) model and favorable rate dynamics. At the consolidated level, revenue growth is expected to have remained healthy, supported by membership expansion and higher capitation rates. Recent strength has been aided by the successful reinstatement of participants who had previously lost Medicaid coverage, which boosted member months and reduced revenue reserves. However, as this tailwind normalizes, growth may increasingly depend on organic enrollment gains and retention improvements. Additionally, while Medicaid rates have been slightly favorable, the broader reimbursement environment remains subject to policy variability, particularly around Medicare risk adjustments. From a cost perspective, medical cost management has emerged as a key driver of margin expansion. The company has demonstrated improved control over inpatient and skilled nursing utilization, alongside benefits from in-house pharmacy operations. These efficiencies are likely to have persisted, though seasonal factors — such as higher flu incidence and elevated inpatient admissions — could pressure medical costs in the near term. Operationally, center-level productivity and SG&A discipline have improved meaningfully through restructuring and better workforce management, which is likely to have contributed to margin expansion. Still, management has indicated that the third quarter is likely to be typically softer due to enrollment seasonality and cost pressures, suggesting some moderation in profitability before reacceleration later in the year. The census growth, participant retention, and continued improvements in revenue integrity will be critical. Initiatives around patient experience and reducing clinical variability could support longer-term growth and margin durability, though these benefits are likely to accrue gradually. Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for INNV. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #3 at present. InnovAge Holding Corp. price-eps-surprise | InnovAge Holding Corp. Quote Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Microbot Medical MBOT has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present. MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure. Henry Schein HSIC has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5. HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure. IDEXX Laboratories IDXX has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report InnovAge Holding Corp. (INNV) : Free Stock Analysis Report Microbot Medical Inc. (MBOT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study was performed at three leading medical centers in the U.S.; Memorial Sloan Kettering Cancer Center (New York, NY), Baptist Hospital of Miami (Miami, FL) and Brigham and Women’s Hospital (Boston, MA). The late-breaking podium presentation was given by Francois Cornelis, M.D., PhD, Director of the Neuro Vascular Interventional Radiology Program at Memorial Sloan Kettering Cancer Center. The data presented concluded that robotic endovascular procedures using LIBERTY® are feasible and significantly minimize radiation exposure. Significant Highlights of the ACCESS-PVI Study: Successful robotic navigation was achieved in every case (N=20), yielding a success rate of 100%, meeting the primary endpoint of the study. No Adverse Device Events (ADE=0%) were reported through the duration of follow-up. Mean difference in radiation exposure between operator and control was (-)29.8 µS, resulting in a mean 92% relative reduction in radiation exposure. Median robotic navigation time to target was 3 minutes. Participating physicians reported LIBERTY® performed as planned with a 100% satisfaction rate. “The ACCESS-PVI data and the performance of the system throughout the study reflect the hard work that the team has put into LIBERTY® over the past few years,” commented Harel Gadot, Chairman, CEO and President. “We are extremely pleased with the results in all aspects. As we shift focus to building our commercial capabilities and preparing for launch, we are confident that LIBERTY® will be well received in the market.” “We are very satisfied with the clinical data, as well as with the investigators’ feedback in terms of the short learning curve and intuitive operation of the device,” commented Dr. Juan Diaz-Cartelle, the Company’s Chief Medical Officer. “We are looking forward to working with interventional physicians and staff upon FDA’s clearance.” LIBERTY® is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S. About Microbot Medical® Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at http://www.microbotmedical.com. Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and the recent announcement of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Investor Contact: [email protected]